# Kenneth Galbraith

> Kenneth Galbraith is a Series B investor at Profound Medical Inc backing Biotechnology. See 12 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Profound Medical Inc](https://shizune.co/investors/profile/profound-medical-inc-2)
- Location: Vancouver, Canada
- Total investments: 12
- Last investment: Apr 2013
- Lead investor: 33%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/kenneth-galbraith-57551a10/

Kenneth Galbraith is a Series B investor at Profound Medical Inc in Vancouver focused on Biotechnology and Health Care. Mr. Galbraith joined Ventures West in 2007 and leads the firm's biotech practice. Mr. Galbraith is a well-known and active member of the North American life sciences community with over 20 years of experience acting as an executive, director, investor and advisor to companies in the biotechnology, medical device, pharmaceutical and healthcaresectors. In 2006, Mr. Galbraith served as the Chairman and Interim CEO of AnorMED, a biopharmaceutical company focused on new therapeutic products in hematology, HIV and oncology, until its sale to Genzyme Corp. in a cash transaction worth almost $600 million. Previously, Mr. Galbraith spent 13 years in senior management with QLT Inc., a global biopharmaceutical company specializing in developing treatments for eye diseases and oncology, retiring in 2000 from his position as Executive VP and CFO. He currently serves as a Director of Alder Biopharmaceuticals, Aquinox Pharmaceuticals, Celator Pharmaceuticals, MacroGenics, NeurAxon and Presidio Pharmaceuticals.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 6 | 50% |
| Health Care | 4 | 33% |
| Therapeutics | 3 | 25% |
| Medical | 2 | 17% |
| Pharmaceutical | 2 | 17% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 4 | 33% |
| Series C | 3 | 25% |
| Series D | 2 | 17% |
| Series A | 1 | 8% |
| Debt Financing | 1 | 8% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 4 | 33% |
| Canada | 2 | 17% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Aquinox Pharmaceuticals | Aquinox Pharmaceuticals Inc., a pharmaceutical company, engages in discovery, development, and commercialization of small molecule therapeutics for the treatment of cancer and inflammatory disease. It offers AQX-MN100, a drug used to treat cancer and inflammatory disease, as well as SH2-containing inositol 5'-phosphatase inhibition program forblood cell recovery. The company was founded in 2004 and is based in Vancouver, Canada. | $18M | Series C | Apr 03, 2013 |  |
| Alder Biopharmaceuticals | Alder's mission is to help alleviate human suffering by generating better and safer antibody therapeutics through novel technologies. Alder plays two roles: As a biopharmaceutical company, Alder uses its proprietary technologies to uniquely identify, develop, produce and market its own antibody therapeutics. The work being done at Aldertoday will help those who suffer from cancer, autoimmune diseases, and inflammatory diseases. As a licensing partner, Alder is revolutionizing the way the pharmaceutical industry discovers, develops and produces antibody therapeutics. Through various licensing agreements, Alder has used its proprietary technology to help major biopharmaceutical partners advance novel therapeutics to the clinic in less time and at lower cost. Alder's licensing strategy also includes identifying strategic partners to assist in the development and marketing of its preclinical and clinical pipeline programs. | $38M | Series D | Apr 19, 2012 |  |
| NeurAxon | NeurAxon, Inc. discovers and develops pain therapeutics targeting neuronal nitric oxide synthase. It has oral products in pipeline addressing acute migraine, neuropathic pain chronic daily headache, inflammatory pain, migraine prophylaxis, and severe pain. The company was founded in 2004 and is headquartered in Toronto, Canada. | $14M | Debt Financing | Sep 30, 2010 |  |
| Celator Pharmaceuticals | Celator Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies to treat cancer. The company focuses on CombiPlex, a drug ratio technology platform that enables to the development of combination therapies. Its products include CPX-1 (Irinotecan HCI-Floxuridine), a treatment for colorectal cancer; and CPX-351(Cytarabine-Daunorubicin), a treatment for acute myeloid leukemia (AML). Celator Pharmaceuticals, Inc. was formerly known as Celator Technologies, Inc. The company was founded in 2000 and is headquartered in Princeton, New Jersey. | $20M | Series D | Sep 01, 2010 |  |
| Aquinox Pharmaceuticals | Aquinox Pharmaceuticals Inc., a pharmaceutical company, engages in discovery, development, and commercialization of small molecule therapeutics for the treatment of cancer and inflammatory disease. It offers AQX-MN100, a drug used to treat cancer and inflammatory disease, as well as SH2-containing inositol 5'-phosphatase inhibition program forblood cell recovery. The company was founded in 2004 and is based in Vancouver, Canada. | $25M | Series B | Jun 17, 2010 |  |
| Celator Pharmaceuticals | Celator Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies to treat cancer. The company focuses on CombiPlex, a drug ratio technology platform that enables to the development of combination therapies. Its products include CPX-1 (Irinotecan HCI-Floxuridine), a treatment for colorectal cancer; and CPX-351(Cytarabine-Daunorubicin), a treatment for acute myeloid leukemia (AML). Celator Pharmaceuticals, Inc. was formerly known as Celator Technologies, Inc. The company was founded in 2000 and is headquartered in Princeton, New Jersey. | $22.5M | Series C | Jul 29, 2008 |  |
| Presidio Pharmaceuticals | Presidio Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the discovery, in-licensing, development and commercialization of novel therapeutics for viral infections, including HCV and HIV. Presidio has raised over $27 million in financing from Panorama Capital, Baker Brothers Investments, Bay City Capital, Ventures West, NexusMedical Partners, and Sagamore Bioventures LLC. | $26M | Series B | Aug 29, 2007 |  |
| NeurAxon | NeurAxon, Inc. discovers and develops pain therapeutics targeting neuronal nitric oxide synthase. It has oral products in pipeline addressing acute migraine, neuropathic pain chronic daily headache, inflammatory pain, migraine prophylaxis, and severe pain. The company was founded in 2004 and is headquartered in Toronto, Canada. | $32M | Series B | Aug 20, 2007 |  |
| Celator Pharmaceuticals | Celator Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies to treat cancer. The company focuses on CombiPlex, a drug ratio technology platform that enables to the development of combination therapies. Its products include CPX-1 (Irinotecan HCI-Floxuridine), a treatment for colorectal cancer; and CPX-351(Cytarabine-Daunorubicin), a treatment for acute myeloid leukemia (AML). Celator Pharmaceuticals, Inc. was formerly known as Celator Technologies, Inc. The company was founded in 2000 and is headquartered in Princeton, New Jersey. | $10M | Series C | Aug 03, 2007 |  |
| Alder Biopharmaceuticals | Alder's mission is to help alleviate human suffering by generating better and safer antibody therapeutics through novel technologies. Alder plays two roles: As a biopharmaceutical company, Alder uses its proprietary technologies to uniquely identify, develop, produce and market its own antibody therapeutics. The work being done at Aldertoday will help those who suffer from cancer, autoimmune diseases, and inflammatory diseases. As a licensing partner, Alder is revolutionizing the way the pharmaceutical industry discovers, develops and produces antibody therapeutics. Through various licensing agreements, Alder has used its proprietary technology to help major biopharmaceutical partners advance novel therapeutics to the clinic in less time and at lower cost. Alder's licensing strategy also includes identifying strategic partners to assist in the development and marketing of its preclinical and clinical pipeline programs. | $16M | Series B | Jul 01, 2006 |  |

10 of 12 investments shown.

## Co-investors
- [H.I.G. Capital](https://shizune.co/investors/profile/hig-capital) — VC Fund, 5 deals together
- [Delphi Ventures](https://shizune.co/investors/profile/delphi-ventures) — VC Fund, 3 deals together
- [GrowthWorks Capital](https://shizune.co/investors/profile/growthworks) — VC Fund, 3 deals together
- [TL Ventures](https://shizune.co/investors/profile/tl-ventures) — VC Fund, 3 deals together
- [Genesys Capital](https://shizune.co/investors/profile/genesys-capital) — VC Fund, 2 deals together
- [Johnson & Johnson Development Corporation](https://shizune.co/investors/profile/johnson-johnson-development-corporation) — VC Fund, 2 deals together

## About Profound Medical Inc

VC Fund · Mississauga, Canada

The Profound Medical team is committed to creating the powerful combination of real-time MR-guidance as the imaging platform and ultrasound as the energy source for delivering non-invasive ablative tools to clinicians. These key technology pillars, linked with intelligent software and robotics, have the potential to fulfill unmet needs of patientsand clinicians in many anatomies and disease states, including prostate cancer, uterine fibroids, and bone metastases. Our mission is to profoundly change the standard of care by creating a tomorrow where clinicians can confidently ablate tissue with precision; a tomorrow where patients have access to safe and effective treatment options, so they can quickly return to their daily lives.

5 contacts available at Profound Medical Inc.

| Name | Title | Profile |
| --- | --- | --- |
| Kenneth Galbraith | Corporate Director | https://shizune.co/investors/profile/kenneth-galbraith |
| Arun Menawat | CEO | https://shizune.co/investors/profile/arun-menawat |
| Goldy Singh | VP of Regulatory Affairs & Quality | https://shizune.co/investors/profile/goldy-singh |
| Hartmut Warnken | VP of International Sales | https://shizune.co/investors/profile/hartmut-warnken |
| Michael Mydra | Vice President, Head of Global Market Access | https://shizune.co/investors/profile/michael-mydra |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Kenneth Galbraith invest in?

Kenneth Galbraith invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series C stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Kenneth Galbraith last invest?

The most recent investment recorded for Kenneth Galbraith closed in Apr 2013. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co